Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Arbutus Biopharma: A Wing And A Prayer
Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.
BioSpace7h
Arbutus Down to ‘Core Team’ After Laying Off More Than Half of Staff
Arbutus is also exiting its corporate headquarters in Pennsylvania and will terminate all in-house scientific research. The ...
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...